Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
In spite of the clinical usefulness of cisplatin (CDDP), there are many occasions in which it is difficult to continue the administration of CDDP due to its nephrotoxicity and neurotoxicity. We examined the incorporation of CDDP into polymeric micelles to see if this allowed the resolution of these disadvantages. Cisplatin was incorporated into polymeric micelles through the polymer-metal complex formation between polyethylene glycol poly(glutamic acid) block copolymers and CDDP (NC-6004). The pharmacokinetics, pharmacodynamics, and toxicity studies of CDDP and NC-6004 were conducted in rats or mice. The particle size of NC-6004 was approximately 30 nm, with a narrow size distribution. In rats, the area under the curve and total body clearance values for NC-6004 were 65-fold and one-nineteenth the values for CDDP (P<0.001 and 0.01, respectively). In MKN-45-implanted mice, NC-6004 tended to show antitumour activity, which was comparable to or greater than that of CDDP. Histopathological and biochemical studies revealed that NC-6004 significantly inhibited the nephrotoxicity of CDDP. On the other hand, blood biochemistry revealed transient hepatotoxicity on day 7 after the administration of NC-6004. Furthermore, rats given CDDP showed a significant delay (P<0.05) in sensory nerve conduction velocity in their hind paws as compared with rats given NC-6004. Electron microscopy in rats given CDDP indicated the degeneration of the sciatic nerve, but these findings were not seen in rats given NC-6004. These results were presumably attributable to the significantly reduced accumulation of platinum in nerve tissue when NC-6004 was administered (P<0.05). NC-6004 preserved the antitumour activity of CDDP and reduced its nephrotoxicity and neurotoxicity, which would therefore seem to suggest that NC-6004 could allow the long-term administration of CDDP where caution against hepatic dysfunction must be exercised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NC-6004 exhibited stable micelles in solution and slowly released cisplatin from the micelle for over 150 h in physiological saline. NC-6004 exhibited a narrow size distribution in solution with a size of 28 nm and loading of cisplatin in NC-6004 was up to 39% LC [153].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A similar polymeric micelle formulation where CDDP was coordinated with PEG-b-P(Glu) [153] evolved into a clinically evaluated polymeric micelle drug, NC-6004 which is described below in Section 5.3.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
The cited source says what the claim attributes to it.
In the citing paper
“Originally developed by Kataoka’s group and NanoCarrier Co., Ltd., NC-6004 is a cisplatin-containing polymeric micelle formed via coordination of platinum drug with the P(Glu) segment of the PEG-b-P(Glu) block copolymer (PEG: 12,000 g/mol and P(Glu): 6,000 g/mol) [153].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Self-citationMaeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · cited 1×
“…polymers or nanoparticles, which are less prone to leak from intact vasculature, and which can be retained in solid tumour tissue for a longer time (enhanced permeability and retention effect (EPR) effect) (Matsumura and Maeda, 1986; Maeda and Matsumura, 1989; Maeda, 2000, 2001).”
BackgroundAmphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,027 · cited 1×
“…93, 678 – 687 & 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00 www.bjcancer.com T ra n sla tio n a l T h e ra p e u tic s the reticuloendothelial system (RES) and to enhance the blood retention profile (Klibanov et al, 1990, 1991; Allen, 1994; Gabizon etal, 1996; Lasic, 1996).”
BackgroundInfluentialdu Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy et al, 2004).”
BackgroundNovel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 710
Self-citation(1998) · British Journal of Cancer · doi:10.1038/bjc.1998.1 · Cited by 654
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623 · cited 1×
“The Phase I clinical trial of adriamycin-incorporating polymeric micelles has been completed (Matsumura et al, 2004).”
BackgroundSelf-citationHamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Self-citationCassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525 · cited 1×
“Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy et al, 2004).”
Background
Cited by
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
“, copper [68] Micellar/liposomal cisplatin [206,207] Gamma-glutamyl transpeptidase inhibitors [76,210] Glutathione transferase inhibitors [74] Anti-oxidants Amifostine [203] BNP7787 [211] N-acetyl cysteine [212] Superoxide dismutase [23,146] Catalase [149] Selenium and Vitamin E [150] Heme oxygenase-1 induction [96] I…”
BackgroundNishiyama, N., & Kataoka, K. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.05.006 · Cited by 1,052
Self-citationNanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
“The high delivery efficiency of the cisplatin-loaded micelles prepared from PEG-b-poly(L-glutamic acid) resulted in the improved antitumor efficacy in subcutaneous tumor models of C26 [57], human gastric cancer (MKN-45) [63] and pancreatic adenocarcinoma”
Self-citationClinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
“A similar polymeric micelle formulation where CDDP was coordinated with PEG-b-P(Glu) [153] evolved into a clinically evaluated polymeric micelle drug, NC-6004 which is described below in Section 5.”
BackgroundPassive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
Lu, Y., & Park, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.08.042 · Cited by 572
Polymeric micelles drug delivery system in oncology
Gong, J., Chen, M., Zheng, Y., Wang, S., & Wang, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.012 · Cited by 570
“8% CDDP release at 24 and 96 h, respectively [17]; (2) significant decrease of IC50 of NC-6004 with the increase of incubation time, while slight change of IC50 of CDDP [17]; (3) a comparable cytotoxicity between CDDP incorporated micelles upon preincubation in physiological saline for 48 h and free CDDP [54].”
BackgroundInfluentialPreclinical and clinical studies of anticancer agent‐incorporating polymer micelles
Matsumura, Y., & Kataoka, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01103.x · Cited by 501
Self-citationPolymeric micelles for nano-scale drug delivery
Miyata, K., Christie, R. J., & Kataoka, K. (2011) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2010.10.009 · Cited by 478
Self-citationNanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
“Notably, histopathological and biochemical studies have not revealed any significant nephrotoxicity of the micelle bound drug, although some transient hepatotoxicity was observed posttreatment [266].”
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
“…that it is preferentially distributed to tumours by enhanced permeability and retention effect (Matsumura and Maeda, 1986; Maeda and Matsumura, 1989; Maeda et al, 2000; Maeda, 2001), and demonstrates significantly lower toxicity than cisplatin and greater anti-tumour activity (Uchino et al, 2005).”
BackgroundSelf-citationNanoparticle Technologies for Cancer Therapy
Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 364
“There are multiple examples of micellar formulations under investigation or in clinical trials, such as Genexol-PM (Kim et al. 2007a; Kim et al. 2004; Lee et al. 2008), NC-6004 (Uchino et al. 2005), NK105 (Hamaguchi et al. 2007), and NK911 (Matsumura et al. 2004; Tsukioka et al. 2002).”
BackgroundNanovehicular Intracellular Delivery Systems
Prokop, A., & Davidson, J. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21270 · Cited by 363
“Cisplatin- and paclitaxel-based formulations were successfully tested in animal studies and currently are in clinical trials.(305,306) Other micellar chemistries are also available.”
Cheetham, A. G., Chakroun, R. W., Ma, W., & Cui, H. (2017) · Chem. Soc. Rev. · doi:10.1039/c7cs00521k · Cited by 367
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice
Kim, J.-H., Kim, Y.-S., Park, K., Lee, S., Nam, H. Y., Min, K. H., Jo, H. G., Park, J. H., Choi, K., Jeong, S. Y., et al. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.014 · Cited by 350
“014 of CDDP is often unsuccessful, however, because of drug toxicity to normal tissues, which induces severe side effects such as acute nephrotoxicity and chronic neurotoxicity [2–4].”
BackgroundNanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences
Subbiah, R., Veerapandian, M., & S. Yun, K. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710794183024 · Cited by 327
“PDLLA-b-methoxy PEG 30 Paclitaxel Various cancer [155]”
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin, S., Nehoff, H., & Greish, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.013 · Cited by 309
Lu, H., Wang, J., Song, Z., Yin, L., Zhang, Y., Tang, H., Tu, C., Lin, Y., & Cheng, J. (2014) · Chem. Commun. · doi:10.1039/c3cc46317f · Cited by 300
Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603855 · Cited by 290
“Moreover, a polymeric micelle carrier system for a drug has the potential to enable the sustained release of the drug inside a tumour following the accumulation of micelles in the tumour tissue (Hamaguchi et al, 2005; Uchino et al, 2005; Koizumi et al, 2006).”
BackgroundSelf-citationPoly (amino acid) micelle nanocarriers in preclinical and clinical studies
Matsumura, Y. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.010 · Cited by 275
Self-citationMetallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Koizumi, F., Kitagawa, M., Negishi, T., Onda, T., Matsumoto, S.-I., Hamaguchi, T., & Matsumura, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1605 · Cited by 256
“In a similar manner to other micellar drugs (19, 23), NK012 showed relatively higher accumulation in organs of the reticuloendothelial system.”
BackgroundResultSelf-citationTseng, C.-L., Su, W.-Y., Yen, K.-C., Yang, K.-C., & Lin, F.-H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.03.010 · Cited by 260
Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs
Gothwal, A., Khan, I., & Gupta, U. (2016) · Pharmaceutical Research · doi:10.1007/s11095-015-1784-1 · Cited by 233
Advances of Cancer Therapy by Nanotechnology
Wang, X., Wang, Y., Chen, Z. G., & Shin, D. M. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.1.1 · Cited by 230
Dugbartey, G. J., Peppone, L. J., & de Graaf, I. A. M. (2016) · Toxicology · doi:10.1016/j.tox.2016.10.001 · Cited by 226
“Although the hydration regimens reduce the toxicities and enhance urine output, there is no substantial evidence in the literature on improvement in GFR or additional benefits of diuretics (Uchino et al., 2005).”
BackgroundStirland, D. L., Nichols, J. W., Miura, S., & Bae, Y. H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.026 · Cited by 225
Yokoyama, M. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903436479 · Cited by 224
“The objectives for the use of the polymeric micelles are different among these six examples: tumor targeting is the objective for four examples (a – d) [96,97], solubilization of water-insoluble drugs is the objective for one other example (e), and circumvention of multi-drug resistance (MDR) is the objective for the…”
BackgroundPolymeric Micelles for Anticancer Drug Delivery
Majumder, N., G Das, N., & Das, S. K. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0008 · Cited by 217
Osada, K., Christie, R. J., & Kataoka, K. (2009) · Journal of The Royal Society Interface · doi:10.1098/rsif.2008.0547.focus · Cited by 218
Self-citationNanoparticle formulations of cisplatin for cancer therapy
Duan, X., He, C., Kron, S. J., & Lin, W. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1390 · Cited by 216
Lv, S., Li, M., Tang, Z., Song, W., Sun, H., Liu, H., & Chen, X. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.08.015 · Cited by 213
“This induces non-specific drug distribution in the body and severe systemic side effects, and therefore chemotherapy often results in an unsatisfactory curative effect due to the side effects of the drugs [2,3].”
BackgroundYang, Y., Liu, X., Ma, W., Xu, Q., Chen, G., Wang, Y., Xiao, H., Li, N., Liang, X.-J., Yu, M., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120456 · Cited by 209
Polymeric micelles for drug targeting
Mahmud, A., Xiong, X.-B., Aliabadi, H. M., & Lavasanifar, A. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701538586 · Cited by 202
“Among different first generation polymeric micellar delivery systems developed for passive targeting and advanced to clinical trials to this point, only two formulations, i.e. NK105 and NC6004 have shown significant favorable changes in the normal biodistribution of encapsulated PXT and CDDP, respectively.”
BackgroundInfluentialNanotechnology and nanocarrier-based approaches on treatment of degenerative diseases
Chowdhury, A., Kunjiappan, S., Panneerselvam, T., Somasundaram, B., & Bhattacharjee, C. (2017) · International Nano Letters · doi:10.1007/s40089-017-0208-0 · Cited by 183
Noncovalent interaction-assisted polymeric micelles for controlled drug delivery
Ding, J., Chen, L., Xiao, C., Chen, L., Zhuang, X., & Chen, X. (2014) · Chem. Commun. · doi:10.1039/c4cc03153a · Cited by 187
Controlled Drug Delivery Systems for Oral Cancer Treatment—Current Status and Future Perspectives
Ketabat, F., Pundir, M., Mohabatpour, F., Lobanova, L., Koutsopoulos, S., Hadjiiski, L., Chen, X., Papagerakis, P., & Papagerakis, S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070302 · Cited by 173
“Also, static light scattering (SLS) measurement exhibited that there is no dissociation of cisplatin-loaded micelles upon dilution and the critical micelles concentration (CMC) was less than 5 × 10−7 [100,103].”
BackgroundDevelopment of polymeric micelles for targeting intractable cancers
Nishiyama, N., Matsumura, Y., & Kataoka, K. (2016) · Cancer Science · doi:10.1111/cas.12960 · Cited by 180
Self-citationClinical translation of nanomedicines
Svenson, S. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.001 · Cited by 175
“NC-6004 is composed of cisplatin and mPEGpoly(glutamic acid), currently recruiting for a Phase 1/2 study of the combination therapy with NC-6004 and gemcitabine in patients with locally advanced or metastatic pancreatic cancer in Asian countries [31].”
BackgroundNanotechnology in the diagnosis and treatment of lung cancer
Cryer, A. M., & Thorley, A. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.010 · Cited by 172
Recent progress in polymer-based platinum drug delivery systems
Xiao, H., Yan, L., Dempsey, E. M., Song, W., Qi, R., Li, W., Huang, Y., Jing, X., Zhou, D., Ding, J., et al. (2018) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2018.07.004 · Cited by 172
Clinical application of polymeric micelles for the treatment of cancer
Varela-Moreira, A., Shi, Y., Fens, M. H. A. M., Lammers, T., Hennink, W. E., & Schiffelers, R. M. (2017) · Materials Chemistry Frontiers · doi:10.1039/c6qm00289g · Cited by 168
Eetezadi, S., Ekdawi, S. N., & Allen, C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.001 · Cited by 166
Mochida, Y., Cabral, H., Miura, Y., Albertini, F., Fukushima, S., Osada, K., Nishiyama, N., & Kataoka, K. (2014) · ACS Nano · doi:10.1021/nn500498t · Cited by 163
Self-citationCabral, H., Nishiyama, N., & Kataoka, K. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.024 · Cited by 161
Self-citationThe Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Amphiphilic poly(l-amino acids) — New materials for drug delivery
Lalatsa, A., Schätzlein, A. G., Mazza, M., Le, T. B. H., & Uchegbu, I. F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.046 · Cited by 163
Nanotechnology and human health: risks and benefits
Cattaneo, A. G., Gornati, R., Sabbioni, E., Chiriva‐Internati, M., Cobos, E., Jenkins, M. R., & Bernardini, G. (2010) · Journal of Applied Toxicology · doi:10.1002/jat.1609 · Cited by 158
“…of other nanoparticulate antineoplastic agents are available to avoid oto- and renal toxicity, in the case of cisplatin (Jehn et al., 2008; Ravaioli et al., 2009; Uchino et al., 2005), or to spare the viral carrier for nucleic acids and small interfering RNA (siRNA) (Bartlett and Davies, 2008).”
BackgroundTargeted Delivery of Cisplatin to Lung Cancer Using ScFvEGFR-Heparin-Cisplatin Nanoparticles
Peng, X.-H., Wang, Y., Huang, D., Wang, Y., Shin, H. J., Chen, Z., Spewak, M. B., Mao, H., Wang, X., Wang, Y., et al. (2011) · ACS Nano · doi:10.1021/nn202410f · Cited by 157
“chloride ions in DDP and was able to be released from the nanoparticles.(32,42) In addition, the Pt concentration”
Zhang, J., & Ma, P. X. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200804135 · Cited by 166
Xu, Y., Han, X., Li, Y., Min, H., Zhao, X., Zhang, Y., Qi, Y., Shi, J. Y., Qi, S., Bao, Y., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b07032 · Cited by 149
Ke, X., Ng, V. W. L., Ono, R. J., Chan, J. M. W., Krishnamurthy, S., Wang, Y., Hedrick, J. L., & Yang, Y. Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.061 · Cited by 146
“Several hybrid PEG–(PGA–drug) prodrug systems have been developed by Kataoka and coworkers including PEG–(PGA–cisplatin) (NC-6004) [137], PEG–(PGA–DACHPt) (NC4016) [1] and PEG–(PGA–SN38) (NK-012) [138].”
Building nanostructures with drugs
Ma, W., Cheetham, A. G., & Cui, H. (2016) · Nano Today · doi:10.1016/j.nantod.2015.11.003 · Cited by 146
Stimulus-responsive self-assembled prodrugs in cancer therapy
Dong, X., Brahma, R. K., Fang, C., & Yao, S. Q. (2022) · Chemical Science · doi:10.1039/d2sc01003h · Cited by 143
Yu, H., Tang, Z., Zhang, D., Song, W., Zhang, Y., Yang, Y., Ahmad, Z., & Chen, X. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.022 · Cited by 141
“This was higher or comparable to theNC-6004 nanoparticles, whichmaintained approximately 13% of the injected dose in the plasma at 24 h [19].”
MethodDhand, C., Prabhakaran, M. P., Beuerman, R. W., Lakshminarayanan, R., Dwivedi, N., & Ramakrishna, S. (2014) · RSC Advances · doi:10.1039/c4ra02861a · Cited by 146
A chemical perspective on the clinical use of platinum-based anticancer drugs
Alassadi, S., Pisani, M. J., & Wheate, N. (2022) · Dalton Transactions · doi:10.1039/d2dt01875f · Cited by 141
Timbie, K. F., Afzal, U., Date, A., Zhang, C., Song, J., Wilson Miller, G., Suk, J. S., Hanes, J., & Price, R. J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.017 · Cited by 130
Zhang, C., Nance, E. A., Mastorakos, P., Chisholm, J., Berry, S., Eberhart, C. G., Tyler, B., Brem, H., Suk, J. S., & Hanes, J. S. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.007 · Cited by 144
Farooq, M. A., Aquib, M., Farooq, A., Khan, D. H., Maviah, M. B. J., Filli, M. S., Kesse, S., Boakye‐Yiadom, K. O., Mavlyanova, R., Parveen, A., et al. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1604535 · Cited by 145
“The reduced toxicity can be elaborated by various facts the micelles are less prone to filtration by nephrons because of the reduced nanoparticle size of about 30 nm, and the lower Cmax for CDDP in uriniferous tubules [48].”
BackgroundYokoyama, M. (2011) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2011.06.002 · Cited by 152
Strategies for improving the payload of small molecular drugs in polymeric micelles
Zhang, Y. X., Ren, T., Gou, J., Zhang, L., Tao, X., Tian, B., Tian, P., Dan-dan, Y., Song, J., Liu, X., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.047 · Cited by 134
A concise review on cancer treatment methods and delivery systems
Bidram, E., Esmaeili, Y., Ranji‐Burachaloo, H., Al-Zaubai, N., Zarrabi, A., Stewart, A. G., & Dunstan, D. E. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101350 · Cited by 140
Cisplatin–alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells
Wang, Y., Zhou, J., Qiu, L., Wang, X., Chen, L., Liu, T., & Di, W. J. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.035 · Cited by 130
Conjugate of Pt(IV)–Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy
Yang, J. J., Sun, X., Mao, W., Sui, M., Tang, J., & Shen, Y. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200597r · Cited by 136
Polymeric drug delivery of platinum-based anticancer agents
Haxton, K. J., & Burt, H. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21611 · Cited by 137
Targeted Albumin-Based Nanoparticles for Delivery of Amphipathic Drugs
Xu, R., Fisher, M. H., & Juliano, R. L. (2011) · Bioconjugate Chemistry · doi:10.1021/bc1002295 · Cited by 132
Targeted nanomedicine in cisplatin-based cancer therapeutics
Han, Y., Wen, P., Li, J., & Kataoka, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.049 · Cited by 131
Self-citation(Nano)platforms in bladder cancer therapy: Challenges and opportunities
Ashrafizadeh, M., Zarrabi, A., Karimi‐Maleh, H., Taheriazam, A., Mirzaei, S., Hashemi, M., Hushmandi, K., Makvandi, P., Zare, E. N., Sharifi, E., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10353 · Cited by 136
Polymeric Micellar Delivery Systems in Oncology
Matsumura, Y. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn116 · Cited by 121
“This finding is believed to be a factor that reduced neurotoxicity following NC-6004 administration as compared with the CDDP administration (23).”
BackgroundSelf-citationPolyether based amphiphiles for delivery of active components
Gupta, S., Tyagi, R., Parmar, V. S., Sharma, S. K., & Haag, R. (2012) · Polymer · doi:10.1016/j.polymer.2012.04.047 · Cited by 132
Satpathy, M., Wang, L., Zieliński, R., Qian, W., Wang, Y. A., Mohs, A. M., Kairdolf, B. A., Ji, X., Capala, J., Lipowska, M., et al. (2019) · Theranostics · doi:10.7150/thno.29964 · Cited by 124
“Increasing evidence shows that biomarker-targeted therapy and nanoparticle drugs have improved delivery into tumors, leading to enhanced therapeutic responses [15-19].”
BackgroundZhao, W., Cong, Y., Li, H., Li, S., Shen, Y., Qi, Q., Zhang, Y., Li, Y., & Ya-jie Tang, A. (2020) · Natural Product Reports · doi:10.1039/d0np00041h · Cited by 120
Subbiah, V., Grilley-Olson, J. E., Combest, A. J., Sharma, N., Tran, R. H., Bobe, I., Osada, A., Takahashi, K., Balkissoon, J., Camp, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1114 · Cited by 118
“Preclinical data also demonstrate that NC-6004 has a favorable tolerability profile (nephrotoxicity and neurotoxicity) and preserved or improved antitumor activity compared with cisplatin (19).”
BackgroundThe pharmacology, toxicology and therapeutic potential of anthraquinone derivative emodin
Ya, C. U. I., Liu-Jing, C. H. E. N., Huang, T., Jian-Qiong, Y. I. N. G., & Li, J. (2020) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(20)30050-9 · Cited by 141
Multifunctionality of lipid-core micelles for drug delivery and tumour targeting
Sawant, R. R., & Torchilin, V. P. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.516276 · Cited by 123
“Poly(D,L-lactide)-b-methoxy-PEG Paclitaxel (Uchino et al. 2005); testosterone, griseofulvin (Kim et al.”
Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment
Callari, M., Aldrich-Wright, J. R., de Souza, P. L., & Stenzel, M. H. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.05.002 · Cited by 120
Yamamoto, T., Yokoyama, M., Opanasopit, P., Hayama, A., Kawano, K., & Maitani, Y. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.07.008 · Cited by 119
An overview of polymeric nanomicelles in clinical trials and on the market
Zheng, X., Xie, J., Zhang, X., Sun, W., Zhao, H., Li, Y., & Wang, C. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.11.029 · Cited by 114
Endo, K., Ueno, T., Kondo, S., Wakisaka, N., Murono, S., Itō, M., Kataoka, K., Kato, Y., & Yoshizaki, T. (2013) · Cancer Science · doi:10.1111/cas.12079 · Cited by 119
“(9,10) The caspase cascade is activated when a CDDP stimulus induces the release of cytochrome c from mitochondria.”
BackgroundResultSelf-citationBiodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer
Desale, S. S., Cohen, S. M., Zhao, Y., Kabanov, A. V., & Bronich, T. K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.026 · Cited by 110
“In the kidney, the primary target organ of CDDP toxicity [33,34], single or binary drug loaded cl-micelles showed significantly lower Pt levels than the free CDDP (Fig.”
Magnetically controlled release of cisplatin from superparamagnetic starch nanoparticles
Likhitkar, S., & Bajpai, A. (2011) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2011.07.053 · Cited by 110
Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine
Wang, Q., Atluri, K., Tiwari, A. K., & Babu, R. J. (2023) · Pharmaceuticals · doi:10.3390/ph16030433 · Cited by 113
“A micelle-based formulation was developed to alter the bio-distribution and PK profile, thereby increasing the tumor accumulation and efficacy [232].”
MethodPeptide-Based Polymer Therapeutics
Duro‐Castaño, A., Conejos‐Sánchez, I., & Vicent, M. J. (2014) · Polymers · doi:10.3390/polym6020515 · Cited by 122
“Not only proteins but also low Mw drugs such as cis-dichlorodiamineplatinum II (CDDP) have also been used to form PICs [142–144].”
MethodScarano, W., Duong, H. T. T., Lu, H., de Souza, P. L., & Stenzel, M. H. (2013) · Biomacromolecules · doi:10.1021/bm400121q · Cited by 111
Translating materials design to the clinic
Hubbell, J. A., & Langer, R. (2013) · Nature Materials · doi:10.1038/nmat3788 · Cited by 112
Driving forces for drug loading in drug carriers
Li, Y., & Li, Y. (2015) · Journal of Microencapsulation · doi:10.3109/02652048.2015.1010459 · Cited by 109
“nephrotoxicity, neurotoxicity and ototoxicity) (Uchino et al., 2005; Plummer et al., 2011; Baba et al., 2012) and demonstrated plasma AUC and tumour accu-”
BackgroundInfluentialPlatinum(II) Drug-Loaded Gold Nanoshells for Chemo-Photothermal Therapy in Colorectal Cancer
Lee, S., & Shieh, M. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b18855 · Cited by 105
Winer, I., Wang, S., Lee, Y.-E. K., Fan, W., Gong, Y., Burgos-Ojeda, D., Spahlinger, G., Kopelman, R., & Buckanovich, R. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1917 · Cited by 99
Xia, F., Hou, W., Zhang, C., Zhi, X., Cheng, J. Q., de la Fuente, J. M., Song, J., & Cui, D. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.12.034 · Cited by 101
Anticancer nanoparticulate polymer‐drug conjugate
Feng, Q., & Tong, R. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10033 · Cited by 105
“[45] Uchino H, Matsumura Y, Negishi T, et al.”
BackgroundShen, Y., Zhan, Y., Tang, J., Xu, P., Johnson, P. A., Radosz, M., Van Kirk, E. A., & Murdoch, W. J. (2008) · AIChE Journal · doi:10.1002/aic.11600 · Cited by 97
Chen, G., Meng, C. L., Lin, K. C., Tuan, H., Yang, H. J., Chen, C.-L., Li, K.-C., Chiang, C., & Hu, Y. C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.11.034 · Cited by 97
“5 mg/kg GOþ10 mg/kg CDDP, n 1⁄4 6) was injected intratumorally using the concentrations described previously [14,21,22].”
MethodSong, W., Li, M., Tang, Z., Li, Q., Yang, Y., Liu, H., Duan, T., Hong, H., & Chen, X. (2012) · Macromolecular Bioscience · doi:10.1002/mabi.201200145 · Cited by 97
Metadata
- Authors
- Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T.
- Affiliations
- National Cancer Center Hospital East (JP)
- NanoCarrier (Japan) (JP)
- Fukushima Medical University (JP)
- The University of Tokyo (JP)
- Kyushu University (JP)
- National Cancer Centre Japan (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2005-09
- Volume
- 93
- Issue
- 6
- Pages
- 678-687
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361620
- OpenAlex
- W1974920077
- Cited by
- 430
- References
- 37
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 20 · 2021: 22 · 2020: 21 · 2019: 20 · 2018: 9 · 2017: 34 · 2016: 27 · 2015: 35 · 2014: 39 · 2013: 32 · 2012: 29
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Health, Labour and Welfare
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- cisplatin, polymeric micelles, nephrotoxicity, neurotoxicity, hepatotoxicity, sensory nerve conduction velocity, antitumour activity, pharmacokinetics, drug toxicity reduction
- MeSH terms
- Animals, Antineoplastic Agents, Body Weight, Brain, Cisplatin, Drug Carriers, Female, Humans, Kidney, Kidney Diseases, Liver, Mice, Inbred BALB C, Mice, Nude, Micelles, Polyethylene Glycols, Tumor Cells, Cultured, Rats, Sprague-Dawley, Neurotoxicity Syndromes, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.